Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS

(H. Lee Moffitt Cancer Center & Research Institute) Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news